AIM AIM ImmunoTech

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress

Provides interested parties the ability to ask questions and submit topics for future videos

OCALA, Fla., March 07, 2024 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced the launch of its featuring of AIM ImmunoTech. The CEO Corner platform is intended to provide additional and in-depth perspective to press releases, corporate developments and development pipeline progress.

“Keeping our stakeholders well informed is absolutely essential to the future success of AIM ImmunoTech,” states Equels. “CEO Corner is a new way for us to connect directly with both current and potential stockholders. CEO Corner segments will provide expanded perspective on press releases, clinical trials and other corporate advancements as we continue to push forward with our development pipeline. We believe in the future of Ampligen and are dedicated to growing value for all stakeholders.”



The CEO Corner is now accessible on the Company’s website .

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit  and connect with the Company on , , and .

A photo accompanying this announcement is available at 



Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
EN
07/03/2024

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provi...

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update Continued progress across pipeline programs with focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or...

23h / 18m 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Present at the Webull Financial Corporate Connect We...

AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech Live video webcast on Wednesday, August 20th at 2:40 PM ET   OCALA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Wednesday, August 20, 2025 at 2:40 PM ET Presenter: Registration Link: About Webull Financial Webull Financial is a leading online brokerage platform committed t...

August 14, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presenta...

AIM ImmunoTech’s Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) There will be presentations on the latest positive progress from AIM’s clinical program in pancreatic cancer, the positive therapeutic effects of AIM’s drug Ampligen on multiple cancer types, and Ampligen’s mechanism of action in oncology Discussion will also feature an abstract and oral presentation on Ampligen’s positive impact on endometriosis, a known precursor to ovarian cancer OCALA, Fla...

August 6, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Drivin...

AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer Approval Primary focus on pancreatic cancer Mid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca’s Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both no significant toxicity and superior PFS and OS Bolstered cash position provides runway to fund operations for approximately 12 months OCALA, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) toda...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering OCALA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (the “Company”), today announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common stock, and Class F warrants to purchase up to 2,000,000 shares of common stock, at a combined public offering price of $4.00 per share (or $3.999 per pre-funded warrant) and accompanying warran...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch